Brooke M. Rock, PhD

Director, Department of Pharmacokinetics & Drug Metabolism @ Amgen Inc.

How Understanding ADME Properties of Multispecific Biologics Can Increase Speed to the Clinic

Roger D. Kamm, PhD

Cecil and Ida Green Distinguished Professor of Biological and Mechanical Engineering @ MIT

Vascular and Lymphatic Barrier Function in the Brain and Subcutaneous Compartments

Mailys De Sousa Mendes, PhD

Senior Research Scientist @ Certara UK

Mechanistic Modeling of Caco-2 Experiments to Estimate Intrinsic Permeability

Li Di, PhD

Research Fellow @ Pfizer, Inc.

Prediction Accuracy of Volume of Distribution Using In Vitro, In Vivo, PBPK and QSAR Methods

Charles Knutson, PhD

Associate Director @ Novartis Institutes for BioMedical Research

Panel Discussion

James Kozloski, PhD

Principal Research Scientist @ IBM

Populations of Models for Virtual Patient/Cohort Construction in ADME/PK

Ryan Pelis, PhD

Senior Investigator I @ Novartis Institutes for BioMedical Research

Tools Toward Predicting Oral Lymphatic Absorption

Haojing Rong, PhD

Vice President of Preclinical Development @ Kymera Therapeutics

The Knowns and Unknowns of ADME/PK of Targeted Protein Degraders

Yuanxin Xu, PhD

Sr. VP of Early Development and Translational Medicine @ Intellia Therapeutics, Inc.

Of Mice and Man: Path to Clinical CRISPR/Cas9 Genome Editing Therapeutic Development

Doug Burdette, PhD

Director of DMPK and Clinical Pharmacology @ Moderna Therapeutics, Inc.

Assessment of Amino Lipid Biodistribution, Metabolism, and Elimination in Rats after LNP IV Administration to Understand In Vivo Fate and Potential for DDI

Dipen Vyas, PhD

Study Director (ADME-Tox) @ BioIVT

Long-term HEPATOPAC® Cultures: Model Validation for ADME-Tox Applications

Panel Discussion:

Expedited Drug Discovery Post-COVID 

 Participants:

Brooke Rock, Amgen

Doug Burdette, Moderna

Li Di, Pfizer

Charlie Knutson, Novartis